Company intelligence / Profile preview
Theradaptive
Frederick, Maryland, United Statestheradaptive.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Theradaptive’s lead product, OsteoAdapt, is in a global Phase 1/2 trial targeting spinal fusion with several FDA Breakthrough Device Designations. Early results have enabled expansion to U.S. and Australian sites and plans are underway for a Phase 3 study by late 2025. The company is also launching dental implant studies and developing additional orthopedic and immuno-oncology programs
- Therapeutic areas
- RheumatologyOncologyOther
- Modalities
- Recombinant proteinBiologicDevice (implantable scaffold)Protein engineering technology (material-binding proteins)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Department of DefenseMaryland Stem Cell Research FundNo major pharma partnerships publicly disclosed as of June 2025.
Beyond the preview
Go deeper on Theradaptive.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Theradaptive.